These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21307149)

  • 1. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer.
    Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
    Clin Cancer Res; 2011 May; 17(10):3293-303. PubMed ID: 21307149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
    Waldman SA; Hyslop T; Schulz S; Barkun A; Nielsen K; Haaf J; Bonaccorso C; Li Y; Weinberg DS
    JAMA; 2009 Feb; 301(7):745-52. PubMed ID: 19224751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.
    Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
    Expert Rev Mol Diagn; 2009 Nov; 9(8):777-85. PubMed ID: 19895223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GUCY2C molecular staging personalizes colorectal cancer patient management.
    Gong JP; Schulz S; Hyslop T; Waldman SA
    Biomark Med; 2012 Jun; 6(3):339-48. PubMed ID: 22731908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular staging estimates occult tumor burden in colorectal cancer.
    Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
    Adv Clin Chem; 2010; 52():19-39. PubMed ID: 21275338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer.
    Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
    J Surg Oncol; 2012 Jul; 106(1):24-30. PubMed ID: 22252429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does stage II colorectal cancer need to be redefined?
    Grothey A
    Clin Cancer Res; 2011 May; 17(10):3053-5. PubMed ID: 21498396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.
    Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
    Cancer; 2012 May; 118(9):2532-40. PubMed ID: 21887684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanylyl cyclase C as a biomarker in colorectal cancer.
    Hyslop T; Waldman SA
    Biomark Med; 2013 Feb; 7(1):159-67. PubMed ID: 23387497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.
    Cagir B; Gelmann A; Park J; Fava T; Tankelevitch A; Bittner EW; Weaver EJ; Palazzo JP; Weinberg D; Fry RD; Waldman SA
    Ann Intern Med; 1999 Dec; 131(11):805-12. PubMed ID: 10610624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of occult metastasis in lymph nodes from colorectal cancer patients: a multiple-marker reverse transcriptase-polymerase chain reaction study.
    Chen G; McIver CM; Texler M; Lloyd JM; Rieger N; Hewett PJ; Sen Wan D; Hardingham JE
    Dis Colon Rectum; 2004 May; 47(5):679-86. PubMed ID: 15037935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients.
    Conzelmann M; Dieterle CP; Linnemann U; Berger MR
    Int J Cancer; 2003 Nov; 107(4):617-28. PubMed ID: 14520701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
    Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y
    Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
    Waldman SA; Cagir B; Rakinic J; Fry RD; Goldstein SD; Isenberg G; Barber M; Biswas S; Minimo C; Palazzo J; Park PK; Weinberg D
    Dis Colon Rectum; 1998 Mar; 41(3):310-5. PubMed ID: 9514425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular staging individualizing cancer management.
    Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
    J Surg Oncol; 2012 Apr; 105(5):468-74. PubMed ID: 22441898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular staging of node negative patients with colorectal cancer.
    Hyslop T; Waldman SA
    J Cancer; 2013; 4(3):193-9. PubMed ID: 23459453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer.
    Carlson MR
    Mol Diagn Ther; 2009; 13(1):11-4. PubMed ID: 19351210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis.
    Gill S; Haince JF; Shi Q; Pavey ES; Beaudry G; Sargent DJ; Fradet Y
    Clin Colorectal Cancer; 2015 Jun; 14(2):99-105. PubMed ID: 25619805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study.
    Sargent DJ; Shi Q; Gill S; Louvet C; Everson RB; Kellner U; Clancy TE; Pipas JM; Resnick MB; Meyers MO; Wu TT; Huntsman D; Validire P; Farooq U; Pavey ES; Beaudry G; Haince JF; Fradet Y
    Clin Cancer Res; 2014 Aug; 20(16):4361-9. PubMed ID: 24919572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph node CXCL17 messenger RNA: A new prognostic biomarker for colon cancer.
    Rashad Y; Olsson L; Israelsson A; Öberg Å; Lindmark G; Hammarström ML; Hammarström S; Sitohy B
    Tumour Biol; 2018 Sep; 40(9):1010428318799251. PubMed ID: 30198422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.